171 related articles for article (PubMed ID: 34201061)
1. Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib.
Grbčić P; Fučkar Čupić D; Gamberi T; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34201061
[TBL] [Abstract][Full Text] [Related]
2. The Sphingosine Kinase 2 Inhibitor ABC294640 Restores the Sensitivity of BRAFV600E Mutant Colon Cancer Cells to Vemurafenib by Reducing AKT-Mediated Expression of Nucleophosmin and Translationally-Controlled Tumour Protein.
Grbčić P; Eichmann TO; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639107
[TBL] [Abstract][Full Text] [Related]
3. Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro.
Car I; Dittmann A; Vasieva O; Bočkor L; Grbčić P; Piteša N; Klobučar M; Kraljević Pavelić S; Sedić M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629086
[TBL] [Abstract][Full Text] [Related]
4. Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF
Wang K; Li Y; Song N; Che X; Hou K; Xu L; Bai M; Wang Q; Wang Y; Zhou Y; Cao M; Liu Y; Zhang J
J Cell Biochem; 2019 Apr; 120(4):5315-5325. PubMed ID: 30320916
[TBL] [Abstract][Full Text] [Related]
5. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
6. Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.
Hanly EK; Rajoria S; Darzynkiewicz Z; Zhao H; Suriano R; Tuli N; George AL; Bednarczyk R; Shin EJ; Geliebter J; Tiwari RK
BMC Res Notes; 2014 Mar; 7():187. PubMed ID: 24673746
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic effects of MEK kinase inhibitor and BRAF kinase inhibitor on
Kim KO; Park WJ; Jung Y; Lee WS
J Chemother; 2020 Dec; 32(8):437-444. PubMed ID: 33052075
[TBL] [Abstract][Full Text] [Related]
8. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs).
Prasetyanti PR; Capone E; Barcaroli D; D'Agostino D; Volpe S; Benfante A; van Hooff S; Iacobelli V; Rossi C; Iacobelli S; Medema JP; De Laurenzi V; Sala G
Oncotarget; 2015 Jul; 6(19):16902-11. PubMed ID: 26160848
[TBL] [Abstract][Full Text] [Related]
9. Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas.
Sinicrope FA; Smyrk TC; Tougeron D; Thibodeau SN; Singh S; Muranyi A; Shanmugam K; Grogan TM; Alberts SR; Shi Q
Cancer; 2013 Aug; 119(15):2765-70. PubMed ID: 23657789
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
11. Involvement of HMGB1 in vemurafenib resistance in thyroid cancer cells harboring BRAF (V600E) mutation by regulating excessive autophagy.
Run L; Wang L; Nong X; Li N; Huang X; Xiao Y
Endocrine; 2021 Feb; 71(2):418-426. PubMed ID: 32666385
[TBL] [Abstract][Full Text] [Related]
12. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
13. EBI-907, a novel BRAF(V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile.
Zhang J; Lu B; Liu D; Shen R; Yan Y; Yang L; Zhang M; Zhang L; Cao G; Cao H; Fu B; Gong A; Sun Q; Wan H; Zhang L; Tao W; Cao J
Cancer Biol Ther; 2016; 17(2):199-207. PubMed ID: 26810733
[TBL] [Abstract][Full Text] [Related]
14. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
[TBL] [Abstract][Full Text] [Related]
15. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
16. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
17. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
18. Combination Treatment with the BRAF
Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
[TBL] [Abstract][Full Text] [Related]
19. Secretome Screening of BRAFV600E-Mutated Colon Cancer Cells Resistant to Vemurafenib.
Car I; Dittmann A; Klobučar M; Grbčić P; Kraljević Pavelić S; Sedić M
Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106808
[TBL] [Abstract][Full Text] [Related]
20. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]